Agata Grochowska: Thromboprophylaxis and Coagulation Challenges in Pancreatic Cancer
Agata Grochowska, Ambassador and Teaching Assistant at Meta-Analysis Academy, shared on LinkedIn about a recent article she and her colleagues co-authored, adding:
”New Publication Alert | Thromboprophylaxis and Coagulation Challenges in Pancreatic Cancer
Published in Journal of Thrombosis and Thrombolysis (IF 2.2)
February 20, 2026
I’m pleased to share our latest review: ‘Coagulation disorders and thromboprophylaxis in pancreatic cancer: a review of current evidence and clinical challenges.’
Pancreatic cancer is still one of the most thrombogenic malignancies.
Venous thromboembolism (VTE) is more than just a clinical problem, playing a crucial role in survival, postoperative recovery, and the ability to deliver systemic therapy.
Highlights from our review:
- Thrombosis associated with pancreatic cancer is among the highest-risk cancers.
- Standard prophylactic dosing is widely recommended, yet largely extrapolated from non-pancreatic cancer data.
- Increased low-molecular-weight heparin (LMWH) treatment plans are effective in reducing VTE in advanced disease, but with no evidence of a survival benefit.
- Direct oral anticoagulants (DOACs) offer convenience but raise concerns regarding gastrointestinal bleeding.
- Post-pancreatectomy VTE occurs in 20-25% of patients within 90 days, with many events occurring after hospital discharge.
- Post-pancreatectomy hemorrhage (PPH) poses a fundamental therapeutic issue: when and how to safely resume anticoagulation remains insufficiently defined.
The central challenge: balancing thrombosis prevention with bleeding risk in one of the most complex oncologic surgical populations.
Our review highlights the urgent need for pancreatic cancer-specific randomized trials and clearer perioperative anticoagulation strategies.
Pancreatic cancer care is not only about resection margins and chemotherapy protocols; it is also about understanding and managing the profound hemostatic imbalance that defines this disease.
A huge thank you to the co-authors: Dr. Julia Kaczorowska, Dr. Maciej Świerczyna, Dr. Wojciech Ciesielski, Prof. Adam Durczyński, Prof. Janusz Strzelczyk, and Prof. Piotr Hogendorf from the Department of General and Transplant Surgery, Medical University of Lodz.”
Title: Coagulation disorders and thromboprophylaxis in pancreatic cancer: a review of current evidence and clinical challenges
Authors: Agata Grochowska, Julia Kaczorowska, Maciej Świerczyna, Wojciech Ciesielski, Adam Durczyński, Janusz Strzelczyk, Piotr Hogendorf
Read the Full Article on Journal of Thrombosis and Thrombolysis
Stay updated on all scientific advances with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies